Alterations in plasma dipeptidyl peptidase IV enzyme activity in depression and schizophrenia: Effects of antidepressants and antipsychotic drugs

Acta Psychiatrica Scandinavica

Volumn 93, Issue 1, 1996, Pages 1-8

  Maes, M ^a,b   De Meester, I ^c   Scharpe S ^c   Desnyder, R ^b   Ranjan, R ^a   Meltzer, H Y ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b Stuivenberg General Hospital   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Antidepressant drug; Depression; Neuroleptic drug; Peptides; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; DIPEPTIDYL PEPTIDASE IV; FLUOXETINE; HALOPERIDOL; IMIPRAMINE; NEUROLEPTIC AGENT; NORTRIPTYLINE; PERPHENAZINE;

ADULT; ARTICLE; CONTROLLED STUDY; DEPRESSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 0030019706     PISSN: 0001690X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0447.1996.tb10612.x     Document Type: Article

References (49)

1. MAES M, DE MEESTER I, VANHOOF O, SCHARPÉ S, BOSMANS E, VANDERVORST C, VERKERK R, MINNER B, SUY E, RAUS J. Decreased serum dipeptidyl peptidase IV activity in major depression. Biol Psychiatry 1991: 30: 577-586.
2. HOPSU-HAVU VK, GLENNER GG. A new dipeptide naphthylamidase hydrolyzing glycyl-propyl-β-naphthylamide. Histochem 1966: 7: 197-201.
3. KATO T, NAGATSU T, FUKASAWA K, HARADA M, NAGATSU I, SAKAKIBARA S. Successive cleavage of N-terminal Arg-Pro and Lys-Pro from substance P but no release of Arg-Pro from bradykinin, by X-Pro dipeptidyl-aminopeptidase. Biochim Biophys Acta 1978: 525: 417-422.
4. FUKASAWA KM, FUKASAWA K, HARADA M. Dipeptidyl aminopeptidase IV, a glycoprotein from pig kidney. Biochim Biophys Acta 1978: 535: 161-166.
5. KULLERTZ G. Die bedeutung der aktivitatsbestimmung des enzyms dipeptidyl-peptidase IV (DP IV) im klinischen laboratorium. Lab Med 1988: 12: 123-130.
6. KASAHARA Y, LEROUX-ROELS G, NAKAMURA R, CHISARI F. Glycylprolyl-diaminopeptidase in human leukocytes: selective occurrence in T lymphocytes and influence on the total serum enzyme activity. Clin Chim Acta 1984: 139: 295-302.
7. WIRTHMULLER R, DENNIG D, OERTEL J, GERHARTZ H. Dipeptidylaminopeptidase IV (DAP IV) activity in normal and malignant T cell subsets as defined by monoclonal antibodies. Scand J Haematol 1983: 31: 197-205.
8. SCHARPÉ S, DE MEESTER I, VANHOOF G et al. Serum DPP IV activity in transplant recipients. Clin Chem 1990: 36: 984-988.
9. DE MEESTER IAJ. Characterization of human lymphocytic dipeptidyl peptidase IV and its identification as the activation antigen CD 26. Antwerp, Ph.D. Thesis; 1992.
10. DE MEESTER I, MERTENS AV, DE CLERCK LS, SCHARPÉ S, BRIDTS CH, STEVENS WJ. Correlations between dipeptidyl peptidase IV and disease activity of rheumatoid arthritis (RA). J Allergy Clin Immunol 1993: 91: 228.
11. KATO T, IWASE K, NAGATSU T, SAKAKIBARA S, FUJITA K. Comparison of X-prolyl dipeptidyl-aminopeptidase activity in human cerebrospinal fluid with that in serum. Experientia 1979: 35: 20-21.
12. SCHOLZ W, MENTLEIN R, HEYMANN E, FELLER AC, ULMER AJ, FLAD HD. Interleukin 2 production by human T lymphocytes identified by antibodies to dipeptidyl peptidase IV. Cell Immunol 1985: 93: 199-211.
13. SCHON E, DEMUTH HU, BARTH A, ANSORGE S. Dipeptidyl peptidase IV of human lymphocytes. Evidence for specific hydrolysis of glycylproline p-nitroanilide in T-lymphocytes. Biochem J 1984: 223: 255-258.
14. SCHON E, MANSFELD HW, DEMUTH HU, BARTH A, ANSORGE S. The dipeptidyl peptidase IV, a membrane enzyme involved in the proliferation of T lymphocytes. Biomed Biochim Acta 1985: 44: 9-15.
15. SCHON E, EICHMANN E, GRUNOW R et al. Dipeptidyl peptidase IV in human T lymphocytes. An approach to the role of a membrane peptidase in the immune system. Biomed Biochim Acta 1986: 45: 1523-1528.
16. SCHON E, JAHN S, KIESSIG ST et al. The role of dipeptidyl peptidase IV in human T lymphocyte activation. Inhibitors and antibodies against dipeptidyl peptidase IV suppress lymphocyte proliferation and immunoglobulin synthesis in vitro. Eur J Immunol 1987: 17: 1821-1826.
17. SCHON E, DEMUTH H-U, EICHMANN E et al. Dipeptidyl peptidase IV in human T lymphocytes. Impaired induction of interleukin 2 and gamma interferon due to specific inhibition of dipeptidyl peptidase IV. Scand J Immunol 1989: 29: 127-132.
18. MAES M. The Interleukin hypothesis of major depression. Progr Psychopharmacol Biol Psychiatry 1995: in press.
19. MAES M, SMITH R, SCHARPÉ S. The monocyte-T lymphocyte hypothesis of major depression. Invited Editorial: Psychoneuroendocrinol 1995: in press.
20. SMITH RS. A comprehensive macrophage-T-lymphocyte theory of schizophrenia. Med Hypotheses 1992: 39: 248-257.
21. MAES M, BOSMANS E, CALABRESE J, MELTZER HY, SMITH R. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res 1995: 29: 141-152.
22. BECKMANN H, SAAVEDRA JM, GATTAZ WF. Low angiotensin-converting enzyme activity (kininase II) in cerebrospinal fluid of schizophrenics. Biol Psychiatry 1984: 19: 679-684.
23. REICHELT KL, PEDERSEN OS, KROGH MH, TEIGLAND GJERSTAD B. Chemical diagnosis, etiology and possible treatment of schizophrenia. In: Dahl CB, et al. eds. Clinical research in psychiatry. Trondheim: University of Trondheim Press, 1987: 85-102.
24. WIEGANT VM, VERHOEF CJ, BURBACH JP, DE WIED D. Increased concentration of alpha- and gamma-endorphin in post-mortem hypothalamic tissue of schizophrenic patients. Life Sciences 1988: 42: 1733-1742.
25. MAES M, SCHARPÉ S, MELTZER HY, CALABRESE J. Plasma prolyl endopeptidase enzyme activity in major depression, schizophrenia and mania: effects of antidepressive drugs, neuroleptics and valproate. Psychiatr Res 1995: in press.
26. WILK S. Prolyl endopeptidase. Life Sciences 1983: 33: 2149-2157.
27. KATO T, OKADA M, NAGATSU T. Distribution of post-proline cleaving enzyme in human brain and the peripheral tissues. Mol Cell Biochem 1980: 32: 117-121.
28. MAES M, GOOSSENS F, SCHARPÉ S, MELTZER HY, D'HONDT P, COSYNS P. Lower serum prolyl endopeptidase enzyme activity in major depression: further evidence that peptidases play a role in the pathophysiology of depression. Biol Psychiatry 1994: 35: 545-552.
29. REICHELT KL, HOLE K, HAMBERGER A et al. Biologically active peptide-containing fractions in schizophrenia and childhood autism. Adv Biochem Psychopharmacol 1981: 28: 627-643.
30. ABASSI Z, GOLOMB E, KEISER HR. Neutral endopeptidase inhibition increases the urinary excretion and plasma levels of endothelin. Metabol 1992: 41: 683-685.
31. WATANABE Y, KOJIMA-KOMATSU T, IWAKI-EGAWA S, FUJIMOTO Y. Increased excretion of proline-containing peptides in dipeptidyl peptidase IV deficient rats. Res Comm Chem Pathol Pharmacol 1993: 81: 323-330.
32. TRAFICANTE LJ, TURNBULL B. Neuropeptide degrading enzyme(s) in plasma and brain: effects of in vivo neuroleptic administration. Pharmacol Res Comm 1982: 14: 341-348.
33. KONKOY CS, OAKES MG, DAVIS TP. Chronic treatment with neuroleptics alters neutral endopeptidase 24.11 activity in rat brain regions. Peptides 1993: 14: 1017-1020.
34. WAHLBECK K, RIMON R, FYHRQUIST F. Elevated angiotensin converting enzyme (kininase II) in the cerebrospinal fluid of neuroleptic treated schizophrenic patients. Schizophr Res 1993: 9: 77-82.
35. FUJITA K, HIRANO M, OCHIAI J et al. Serum glycylproline p-nitroanilidase activity in rheumatoid arthritis and systemic lupus erythematosus. Clin Chem 1987: 88: 15-20.
36. KORANYI L, WALENTIN S, HEPP J, ENDROCZI E. Changes of dipeptidyl peptidase (DP IV) activity in the T lymphocytes of rats following administration of ACTH, dexamethasone and opiates. Exp Clin Endocrinol 1989: 93: 61-68.
37. LOJDA Z. Dipeptidyl peptidase of human lymphocytes. Czech Med 1988: 11: 181-194.
38. MAES M, SCHARPÉ S, DE MEESTER I et al. Components of biological variation in plasma prolyl endopeptidase and dipeptidyl peptidase activity in healthy man. Clin Chem 1994: 40: 1686-1691.
39. AMERICAN PSYCHIATRIC ASSOCIATION. Diagnostic and statistical manual of mental disorders. Washington, DC: APA: 1987.
40. ENDICOTT J, SPITZER RL. A diagnostic interview; the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 1978: 35: 837-844.
41. RHOADES HM, OVERALL JE. The semistructured BPRS interview and rating guide. Psychopharmacol Bull 1988: 10: 101-104.
42. HAMILTON M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960: 23: 56-61.
43. NAGATSU T, HINO M, FUYAMADA H et al. New chromogenic substrates for X-Pro dipeptidyl aminopeptidase. Anal Biochem 1976: 74: 466-476.
44. GOOSSENS F, DE MEESTER I, VANHOOF G, SCHARPÉ S. A sensitive method for the assay of serum prolyl endopeptidase. Eur J Clin Chem Clin Biochem 1992: 30: 235-238.
45. HOWELL DC. Multiple comparisons among treatment means. In: HOWELL DC, ed. Statistical methods for psychology. Boston: Duxbury Press, 1982: 289-307.
46. MAES M, SCHARPÉ S, MELTZER HY, SUY E, COSYNS P, CALABRESE J. Lower angiotensin converting enzyme activity in melancholic subjects: a pilot study. Biol Psychiatry 1992: 32: 621-624.
47. SAELID G, HAUG JO, HEIBERG T, REICHELT KL. Peptide containing fractions in depression. Biol Psychiatry 1985: 20: 254-256.
48. NEMEROFF CB, BERGER PA, BISSETTE G. Peptides in schizophrenia. In: MELTZER HY, ed. Psychopharmacology, the third generation of progress. New York: Raven Press, 1987: 727-743.
49. DRYSDALE A, DEACON R, LEWIS P, OLLY S, ELECTRICWALA A, SHERWWOD R. A peptide containing fraction of plasma of schizophrenic patients which binds to opiate receptors and induces hyperactivity in rats. Neuroscience 1982: 7: 1567-1574.